Capstone Holding Corp.·Basic Materials

NEW YORK--(BUSINESS WIRE)--Capstone Holding Corp. (NASDAQ: CAPS), a tech-enabled building products distribution platform, today reported financial and operating results for the first quarter of 2026. Q1 revenue grew 60% year-over-year to $12.6 million, gross profit grew 124% to $3.0 million, and gross margin expanded 670 basis points to 23.5%—the strongest first-quarter gross margin Capstone has reported in four years. Results reflect the first full quarter of contribution from Carolina Stone a.

NEW YORK--(BUSINESS WIRE)--Capstone Holding Corp. (NASDAQ: CAPS), a tech-enabled building products distribution platform, today announced that it will delay the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, to allow additional time to finalize its quarterly financial statements and complete the related interim review. The Company currently expects to file the Form 10-Q and publish related investor materials no later than Wednesday, May 20, 2026. Capstone rema.

NEW YORK--(BUSINESS WIRE)--Capstone Holding Corp. (NASDAQ: CAPS), a tech-enabled building products distribution platform, today published an investor FAQ on the Company's website detailing recent progress on its convertible debt, working capital facilities, and FY2026 outlook. A key disclosure in the FAQ is that as of May 1, approximately 72% of the original convertible-note principal has been converted, leaving $1.90 million outstanding. The FAQ addresses questions submitted by shareholders fo.

MIDTERMS HORSERACE LOCKED IN A DEAD HEAT 50-50 TRUMP APPROVAL STEADY AT 46 PERCENT AMONG LIKELY MIDTERM VOTERS AND 80 PERCENT WITH GOP VOTERS 85% OF VOTERS ARE CONCERNED COST OF LIVING WILL RISE GIVEN GEOPOLITICAL TENSIONS 52% OF VOTERS SUPPORT U.S. MILITARY AIRSTRIKES ON IRAN, WITH 54% VIEWING THEM AS JUSTIFIED 79% OF VOTERS THINK TRUMP WAS RIGHT TO AGREE TO A TEMPORARY CEASEFIRE IN IRAN 74% SAY THE U.S. IS WINNING OVER IRAN, WITH 63% AFFIRMING THE U.S. SHOULD CONTINUE ITS BLOCKADE IF IRAN REFUSES TO GIVE UP ITS URANIUM 64% OF VOTERS BELIEVE THAT IRANIAN LEADERSHIP IS NOW SPLIT INTO COMPETING FACTIONS, AND 60% SAY IRAN IS UNLIKELY TO GIVE UP ITS NUCLEAR PROGRAM DESPITE PRESSURE 66% OF VOTERS SUPPORT AN INTERNATIONAL NAVAL FORCE TO SECURE THE FREE MOVEMENT OF SHIPS IN THE STRAIT OF HORMUZ 74% OF VOTERS HAVE A FAVORABLE VIEW OF THEIR OWN COUNTRY, BUT ONLY 55% OF FEMALE GEN Z SHARE THE SAME VIEW NEW YORK, NY AND CAMBRIDGE, MA / ACCESS Newswire / April 28, 2026 / Stagwell (NASDAQ:STGW) today released the results of the April Harvard CAPS / Harris poll, a monthly collaboration between the Center for American Political Studies at Harvard (CAPS) and the Harris Poll and HarrisX. President Donald Trump's approval rating is at 42%, his lowest in the past year, though support among likely midterms voters and Republicans remains steady.

NEW YORK--(BUSINESS WIRE)--Capstone Holding Corp. (NASDAQ: CAPS), a tech-enabled building products distribution platform, will publish an investor FAQ during the week of May 4, addressing key questions from its shareholder base. The FAQ will provide additional detail on the Company's recent earnings and 2026 guidance, which includes 54% revenue growth and approximately 4x EBITDA growth. Ahead of publication, Capstone is inviting shareholders to submit questions by emailing investors@capstonehol.

NEW YORK--(BUSINESS WIRE)--Capstone Holding Corp. (NASDAQ: CAPS), a tech-enabled building products distribution platform, today announced financial and operating results for the fourth quarter and full year ended December 31, 2025. The Company closed FY2025 with ~$46.9 million in revenue and gross margin expanding to 23.0%, reflecting acquisition-driven scale and a higher-margin product mix. For FY2026, Capstone expects revenue to rise 54% to $72.1 million, gross margin to reach 26%, and EBITDA.
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.
Basic Materials
Construction Materials
36
1993-01-28
-1.59